Tyra Biosciences Valuation Multiples

Tyra Biosciences Overview

About Tyra Biosciences

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company’s in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Founded

2018

HQ

Employees

60

Website

tyra.bio

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: —

EBITDA: ($137M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Tyra Biosciences Financials

Tyra Biosciences reported last 12-month revenue of — and negative EBITDA of ($137M).

In the same LTM period, Tyra Biosciences generated — in gross profit, ($137M) in EBITDA losses, and had net loss of ($126M).

Tyra Biosciences P&L

In the most recent fiscal year, Tyra Biosciences reported revenue of — and EBITDA of ($132M).

Tyra Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

Tyra Biosciences Stock Performance

Tyra Biosciences has current market cap of $2B, and enterprise value of $2B.

Tyra Biosciences' stock price is $35.25.

Tyra Biosciences Valuation Multiples

Tyra Biosciences trades at (11.7x) EV/EBITDA.

Tyra Biosciences Financial Valuation Multiples

As of March 21, 2026, Tyra Biosciences has market cap of $2B and EV of $2B.

Equity research analysts estimate Tyra Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Tyra Biosciences has a P/E ratio of (15.0x).

Tyra Biosciences Margins & Growth Rates

Tyra Biosciences' revenue in the last fiscal year grew by —.

Tyra Biosciences' revenue per employee in the last FY averaged $0.0M.

Tyra Biosciences Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Tyra Biosciences M&A Activity

Tyra Biosciences acquired XXX companies to date.

Last acquisition by Tyra Biosciences was on XXXXXXXX, XXXXX. Tyra Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Tyra Biosciences Investment Activity

Tyra Biosciences invested in XXX companies to date.

Tyra Biosciences made its latest investment on XXXXXXXX, XXXXX. Tyra Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).